Dynavax to Report Third Quarter 2024 Financial Results and Host Conference Call on November 7, 2024
JMP Securities Maintains Dynavax Technologies(DVAX.US) With Buy Rating, Maintains Target Price $29
State Street Corp's Strategic Reduction in Dynavax Technologies Holdings
H.C. Wainwright Maintains Dynavax Technologies(DVAX.US) With Buy Rating, Maintains Target Price $29
Dynavax Technologies Corp (DVAX) Q2 2024 Earnings Call Highlights: Record HEPLISAV-B Sales and ...
Morgan Stanley's List of Tax Loss Selling Stocks
Express News | Deep Track Biotechnology Master Fund, Ltd. Reports 9.56% Stake in Dynavax Technologies Corp as of Sept 16- SEC Filing
Federated Hermes, Inc. Reduces Stake in Dynavax Technologies Corp
50 Stocks That May See Selling Pressure as Investors Begin Looking to Book Tax Losses
Express News | Lantheus Holdings : Board Will Be Comprised of Ten Directors
Lantheus Appoints Julie Eastland as New Board Member
Shingles Therapeutics Pipeline Market Insights Report 2024 Featuring Zhuhai Trinomab, Nobelpharma, Dynavax Technologies, Jiangsu Rec-Biotechnology, Moderna, Curevo, and Amytrx Therapeutics
Dynavax Technologies Corporation Just Recorded A 28% EPS Beat: Here's What Analysts Are Forecasting Next
Assessing Dynavax Technologies: Insights From 4 Financial Analysts
Express News | Goldman Sachs Maintains Neutral on Dynavax Technologies, Lowers Price Target to $15
Several Dynavax Technologies Insiders Sell Shares Sending Potential Negative Signal
HC Wainwright & Co. Reiterates Buy on Dynavax Technologies, Maintains $29 Price Target
Dynavax Technologies Analyst Ratings
Earnings Call Summary | Dynavax Technologies(DVAX.US) Q2 2024 Earnings Conference
Dynavax's Market Dominance and Buoyant Growth Prospects Affirm Buy Rating